P-Tau217 Outperforms Other Blood-Based Biomarkers To Identify Which Patients May Benefit Most From Anti-Amyloid Alzheimer’s Drugs, Study Shows

MedPage Today (12/5, George) reports “plasma phosphorylated tau 217 (p-tau217) outperformed p-tau181, p-tau231, and other blood-based biomarkers to identify which patients might benefit most from anti-amyloid Alzheimer’s drugs, a cohort study showed.” The research found “plasma p-tau217 helped rule out two groups who would not likely benefit: those who were amyloid-negative, and those who were amyloid-positive but had a high tau burden.” The findings were published in JAMA Neurology.